What is Exacta^™?

Exacta^™ is a comprehensive genomic test designed to identify key genetic alterations and pathways driving cancer, helping reveal which treatments may work best.

It integrates genomic alterations in 500+ genes with expression changes across 20,802 genes to identify actionable mutations, active pathways and sophisticated treatment strategies, including for difficult refractory cancers.

Built for Complex Clinical Decision-Making

• Therapy Prioritisation: Ranks treatments by predicted efficacy and tolerability, not only mutation presence.
• Biological Context: Interprets alterations within tumour-wide signalling networks.
• Decision Confidence: Connects molecular evidence with functional response.
• Beyond Standard Care: Reveals options when routine pathways are limited.

A Different Approach to Precision Oncology

• Network-Level Understanding: Maps interactions between genes, pathways and tumour behaviour.
• Dynamic Tumour Profiling: Captures what is altered and how it influences progression.
• Functional Validation: Tests real tumour response to validate molecular predictions.
• Therapy Optimisation: Selects drug combinations balancing efficacy and toxicity.

Clinical Applications Across the Treatment Journey

• Initial strategy design for biologically aggressive cancers.
• Treatment-failure analysis to identify hidden resistance.
• Re-treatment planning after relapse or progression.
• Chemotherapy decision support using live tumour response.
• Combination-strategy development to identify synergistic options.

Tissue-Based Multi-Analyte Analysis

Deep tumour interrogation at source:

• Tumour DNA/RNA: 511 genes covering SNAs, indels, CNAs, fusion transcripts, TMB and HRD.
• Transcriptomic profiling across 20,802 genes.
• Immunohistochemistry and histopathological analysis.
• In-vitro chemosensitivity testing on live tumour cells.
• CTC enumeration, immunocytochemistry and pharmacogenetics guidance.
• Cell-free total nucleic-acid analysis across 52 genes.

Blood-Based Multi-Analyte Analysis

Non-invasive systemic tumour profiling:

• Cell-free total nucleic acids: 411 genes, including bTMB.
• Exosomal transcriptomic profiling across 20,802 genes.
• In-vitro chemosensitivity testing on live tumour cells.
• CTC enumeration and immunocytochemistry analysis.
• Pharmacogenetics guidance.
• Germline MMR and BRCA1/2 analysis.

Why Multi-Layered Analysis Changes Outcomes

Most tests identify mutations. Exacta^™ identifies what may work.

A tumour’s behaviour cannot always be predicted by DNA mutations alone. Exacta combines what is altered through genomics, what is active through transcriptomics and what actually works through functional testing.

This helps avoid ineffective treatments, reduce trial-and-error and improve the likelihood of response in advanced settings.

From Sample to Strategy

1. Sample acquisition: Blood and/or tumour tissue collection.
2. Multi-level analysis: Genetic, transcriptional and functional evaluation.
3. Systems integration: Modelling tumour behaviour and vulnerabilities.
4. Therapy mapping: Aligning vulnerabilities with available options.
5. Clinical reporting: Clear, ranked recommendations for personalised planning.